🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ken Fisher’s CMPX Holdings & Trades

First Buy
Q1 2026
Duration Held
1 Quarters
Largest Add
Q1 2026
+1.35 M Shares
Current Position
1.35 M Shares
$7.13 M Value

Ken Fisher's CMPX Position Overview

Ken Fisher (via Fisher Asset Management, LLC) currently holds 1.35 M shares of Compass Therapeutics, Inc. (CMPX) worth $7.13 M, representing 0.00% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Ken Fisher has initiated a new position in CMPX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Ken Fisher's Compass Therapeutics (CMPX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Compass Therapeutics (CMPX) Trades by Ken Fisher

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +1.35 M New Buy 1.35 M $5.29

Ken Fisher's Compass Therapeutics Investment FAQs

Ken Fisher first purchased Compass Therapeutics, Inc. (CMPX) in Q1 2026, acquiring 1,348,259 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher has held Compass Therapeutics, Inc. (CMPX) for 1 quarters since Q1 2026.

Ken Fisher's largest addition to Compass Therapeutics, Inc. (CMPX) was in Q1 2026, adding 1,348,259 shares worth $7.13 M.

According to the latest 13F filing for Q1 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 1,348,259 shares of Compass Therapeutics, Inc. (CMPX), valued at approximately $7.13 M.

As of the Q1 2026 filing, Compass Therapeutics, Inc. (CMPX) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.

Ken Fisher's peak holding in Compass Therapeutics, Inc. (CMPX) was 1,348,259 shares, as reported at the end of Q1 2026.